Completed

Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Urogenital Diseases+35

+ Genital Diseases

+ Adnexal Diseases

Over 1 Months
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: September 1996
See protocol details

Summary

Principal SponsorNational Cancer Institute (NCI)
Last updated: June 18, 2023
Sourced from a government-validated database.Claim as a partner

Study start date: September 19, 1996

Actual date on which the first participant was enrolled.

Background: Patients enrolled on CCR clinical protocols may require long term follow-up to assess outcome (e.g., survival) or the effects of prior therapy. Keeping the primary treatment protocols open after accrual is complete in order to follow patients for long term outcome is an administrative burden on investigators and the IRB. Objectives: -To provide follow-up for patients who are long term survivors previously enrolled Center for Cancer Research (CCR) trial but who may not currently be enrolled on a research protocol. Eligibility: -Patients who were previously enrolled on a CCR protocol and who are not eligible for an active NCI intramural primary research protocol. Design: The medical procedures/tests will be based on the patient's diagnosis, treatment and supporting clinical information. This is a follow-up study in which only standard tests and procedures are to be performed. Clinical information that is relevant to the patients prior protocols will be collected for research purposes. Procedures that entail more than minimal risk to the patient should not be performed for research purposes on this protocol.

Principal SponsorNational Cancer Institute (NCI)
Last updated: June 18, 2023
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

1031 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 1 Months

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesAdnexal DiseasesBreast DiseasesEndocrine System DiseasesEndocrine Gland NeoplasmsFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGenital Diseases, MaleGenital Neoplasms, FemaleGenital Neoplasms, MaleGonadal DisordersHemic and Lymphatic DiseasesImmune System DiseasesImmunoproliferative DisordersLymphatic DiseasesLymphoproliferative DisordersNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueOvarian DiseasesProstatic DiseasesSkin DiseasesSkin NeoplasmsUrogenital NeoplasmsSkin and Connective Tissue DiseasesNeuroectodermal TumorsNevi and MelanomasNeuroendocrine TumorsFemale Urogenital DiseasesMale Urogenital DiseasesBreast NeoplasmsLymphomaMelanomaNeoplasmsOvarian NeoplasmsProstatic Neoplasms

Criteria

ELIGIBILITY CRITERIA: Patients of any age who were previously enrolled on a CCR protocol. Not eligible for or unwilling to participate in an active NCI intramural primary research protocol. CCR investigator decides it is in the best interests of the patient and the CC for the patient to be seen in follow-up visits at the NIH. Patient or Legally Authorized Representative (LAR)/guardian is able to provide informed consent.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

National Institutes of Health Clinical Center

Bethesda, United StatesOpen National Institutes of Health Clinical Center in Google Maps
CompletedOne Study Center